The Food and Drug Administration granted 510(k) clearance to Great Basin
Scientific Inc.'s (Nasdaq: GBSN) molecular diagnostic test for Group B
Streptococcus. The stock price surged $1.44 to close at $4.98.
Great Basin Scientific receives FDA clearance
April 22, 2015 at 17:33 PM EDT
